A kidney cancer tumor is not just made up of cancer cells. Surrounding and intertwined with the tumor is a complex ecosystem of immune cells, blood vessels, connective tissue, and other supporting cells - collectively called the tumor microenvironment (TME). This neighborhood profoundly influences how the tumor grows, spreads, and responds to treatment.
Kidney cancer (renal cell carcinoma, or RCC) is known for having an especially rich and active inflammatory environment. Many established indicators of poor prognosis in kidney cancer - such as high platelet counts (thrombocytosis), low red blood cell levels (anemia), and elevated white blood cells - are also signs of systemic (whole-body) inflammation. But the biological connection between tumor biology and these systemic signs has been poorly understood.
The challenge in studying the tumor microenvironment is separating it from the cancer cells themselves. Standard tumor biopsy samples are a mixture of cancer cells, immune cells, normal kidney tissue, and other cell types. Without separating these components, it is hard to determine which genes belong to the immune environment versus the cancer cells.
Previous computational methods for separating these components had important limitations: they often relied on gene signatures derived from other cancer types, and many of those gene signatures turned out to be poorly specific for kidney cancer. This study developed a new, empirically validated approach tailored specifically to kidney cancer to solve this problem.
The key innovation of this study was the use of tumorgrafts (also called patient-derived xenografts, or PDX) - a technique where a patient's actual tumor tissue is transplanted into a mouse host. Because only human cancer cells survive and grow in the mouse, while the mouse's own immune and support cells replace the surrounding tissue, researchers can clearly distinguish human cancer cell gene activity from the surrounding immune environment.
The team created matched sets of three samples from each of 35 kidney cancer patients: the original patient tumor, the tumorgraft grown in a mouse, and adjacent normal kidney tissue. By comparing gene activity across these three samples, they could mathematically calculate the gene expression profile that belongs specifically to the immune and stromal (support tissue) component - the tumor microenvironment.
To perform this separation, the team developed a new computational algorithm called DisHet (Dissecting Heterogeneous bulk tumors), based on a Bayesian statistical model. Unlike previous two-component methods, DisHet properly accounts for all three components present in a tumor: cancer cells, immune and stromal cells, and normal tissue contamination. This three-component approach is more accurate and more realistic.
The accuracy of DisHet was validated in multiple ways - including checking that its predictions matched microscopic examination of tumor sections, agreed with genetic mutation patterns detected in the same samples, and correlated with immune cell counts confirmed by staining tissue samples in the laboratory. The results were highly consistent, validating the algorithm's reliability.
One of the study's most surprising findings was that 65% of previously used immune signature genes - those from widely accepted databases like the Immunome - were not actually expressed at meaningful levels in the kidney cancer immune environment. Using signature genes that don't work in kidney cancer would lead to inaccurate assessments of the immune landscape in these tumors.
Using DisHet, the researchers identified a set of 2,080 novel immune and stromal genes that are genuinely expressed in the kidney cancer microenvironment - with 610 of these being completely new discoveries not found in any prior published immune signature database. These genes provide a much more accurate picture of kidney cancer's immune landscape.
The new gene set - called eTME (empirically defined Tumor Microenvironment) - was validated against single-cell RNA sequencing data from actual kidney cancer patient samples. This gold-standard validation confirmed that the eTME genes correctly identified and characterized different immune cell types present in kidney tumors, including T cells, NK cells (natural killer cells), B cells, macrophages, and neutrophils.
The finding that kidney cancer has its own unique immune gene signature underscores a broader principle: tools developed for one type of cancer cannot be directly applied to others. Kidney cancer's immune environment has its own biology that required its own empirically grounded analysis to characterize properly.
Applying the eTME gene signature to over 884 kidney cancer samples from the large public TCGA database, the study identified two fundamentally different types of kidney cancer based on their immune environment. The first, called the Inflamed Subtype (eTME-IS), was packed with immune cells - including regulatory T cells (Tregs), natural killer cells, Th1 helper T cells, neutrophils, macrophages, B cells, and cancer-fighting CD8+ T cells.
Despite having more immune cells present, the Inflamed Subtype did not correspond to better cancer control - quite the opposite. The eTME-IS tumors were associated with more aggressive cancer biology, including infiltrative tumor borders (visible on MRI/CT imaging) and more necrosis (dead tissue within the tumor) - both signs of aggressive disease. The second subtype - Non-Inflamed (eTME-NIS) - had more angiogenesis (blood vessel growth) and different immune cell composition.
The Inflamed Subtype was strongly enriched for mutations in BAP1, a tumor suppressor gene whose loss is linked to more aggressive kidney cancers. In contrast, mutations in PBRM1 - a different kidney cancer gene - were more common in the Non-Inflamed subtype. This distinction links specific genetic mutations to specific patterns of immune infiltration, suggesting that tumor genetics actively drive the immune environment.
The Inflamed Subtype was also found across different types of kidney cancer - not just clear-cell RCC but also papillary RCC (especially the more aggressive type 2 variant) and chromophobe RCC. This pan-RCC inflamed subtype represents a shared biological state that cuts across different kidney cancer subtypes and could represent a common treatment target.
A fundamental question in cancer biology is whether the immune cells surrounding a tumor are randomly recruited or whether the tumor itself actively shapes the immune response. This study provided compelling evidence that tumor cells actively drive the inflammatory response in kidney cancer.
When kidney tumors from the Inflamed Subtype were transplanted into mice (where the immune environment is different from humans), the mouse immune cells recruited to the tumorgraft matched the pattern seen in human tumors - the same types of immune cells (particularly neutrophils and NK cells) infiltrated the tumors in mice. Critically, different tumors from the same patient recruited similar immune cells, while tumors from different patients recruited different patterns of immune cells.
This consistency - same patient, same immune pattern - strongly suggests that tumor cells carry specific signals that attract particular types of immune cells. The biological instructions are encoded in the cancer cells themselves, not determined by chance or by host factors. This finding has important implications for understanding why some tumors become so inflamed.
The researchers also found that an important immune signal called the IFN-gamma (interferon-gamma) signature was activated in Inflamed Subtype tumors. IFN-gamma signaling is associated with immune activity and - importantly - has been shown to predict response to checkpoint immunotherapy drugs like nivolumab and ipilimumab. This suggests that the Inflamed Subtype may be more responsive to these treatments.
One of the most clinically meaningful findings of this study was a direct link between the tumor's inflammatory subtype and simple blood test abnormalities that doctors already use to assess kidney cancer prognosis. Patients with the Inflamed Subtype showed higher platelet counts (thrombocytosis) and lower hemoglobin levels (anemia) - two well-established prognostic markers in kidney cancer.
Previously, doctors knew that thrombocytosis and anemia predicted poor outcomes in kidney cancer patients, but the biological reason was unclear. This study provides the missing connection: these blood abnormalities are systemic manifestations of tumor-driven inflammation. The tumor is releasing signals that alter the entire body's blood composition, not just the local immune environment.
Inflamed Subtype patients also had lower levels of albumin (a blood protein that falls in states of chronic inflammation and malnutrition) and lower sodium levels - both additional markers of aggressive cancer biology. These findings help explain why multiple different blood test abnormalities cluster together in some kidney cancer patients.
This missing link - connecting tumor genetics, to local immune cell infiltration, to systemic blood test changes, to prognosis - is exactly what the study title describes. It means that routine blood tests already provide indirect information about a patient's tumor immune environment, and that patients with these abnormal blood values likely have the Inflamed Subtype of kidney cancer.
Despite having a worse prognosis overall, the Inflamed Subtype of kidney cancer may paradoxically be the subtype most likely to respond to immunotherapy. The IFN-gamma immune signature that characterizes Inflamed Subtype tumors is the same signature that predicts response to checkpoint inhibitors like nivolumab and pembrolizumab. The heavy immune cell presence in these tumors - though not effectively controlling the cancer - may provide the immune infrastructure that checkpoint drugs can activate.
The link between BAP1 mutations and the Inflamed Subtype also suggests that genetic testing for BAP1 could help identify patients most likely to benefit from immunotherapy. Mouse model experiments showed that BAP1-deficient tumors recruited more CD4+ and CD8+ T cells than PBRM1-mutant tumors, suggesting a causal relationship between BAP1 loss and immune activation that could be therapeutically exploited.
This study also established a freely available software tool (DisHet) and eTME gene signature database that other researchers can use. More broadly, it demonstrates the value of tumorgraft models as a research tool - not just for testing drugs, but for precisely characterizing the biology of individual patient tumors in ways that standard tissue analysis cannot achieve.
For kidney cancer patients, the key takeaway is that the tumor's immune environment is not random - it is shaped by the specific genetic makeup of the cancer. Understanding whether a patient's tumor falls into the Inflamed or Non-Inflamed subtype may eventually guide decisions about whether immunotherapy or anti-angiogenic therapy is the better first choice, moving kidney cancer treatment one step closer to true personalized medicine.